Nucleotide metabolism has been targeted for many years and in various clinical
settings, including cancer. The increased knowledge of certain enzymes involved in
this metabolism and associated cellular processes accumulated over the last few years,
gives important information related to the druggability of certain proteins and the use of
inhibitors for others. Here, we review recent data on such enzymes with a major interest
in drug development, i.e. SAMHD1 and the proteins of the NUDIX family. These include
information on their roles in cancer progression, correlations with clinical outcomes
in cancer patients, and the development and study of enzymatic inhibitors.
Keywords: NUDIX, MTH1, SAMHD1, cancer, treatment, inhibitors.
Rights & PermissionsPrintExport